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Abstract
Mounting an immune response sufficient to eradicate a tumor is the goal of modern immunotherapy. Single agent
therapies with checkpoint inhibitors or costimulatory molecule agonists are effective only for a small portion of all
treated patients. Combined therapy, e.g., CTLA-4 and PD-1 checkpoint blockade, is a more effective treatment modality,
but in preclinical studies OX40 agonism with CTLA-4 blockade using monoclonal antibodies (aOX40/aCTLA-4) failed to
induce tumor regression of larger, more established tumors. We hypothesized that administration of a vaccine with a
tumor-associated antigen targeted to the appropriate antigen presenting cell could make combined aOX40/aCTLA-4
therapy more effective. We administered an antibody-based vaccine targeting HER2 to the DEC-205 endocytic receptor
on cross-presenting dendritic cells (anti-DEC-205/HER2; aDEC-205/HER2) and a potent adjuvant (poly (I:C)) to assist with
maturation, along with aOX40/aCTLA-4 therapy. This therapy induced complete regression of established tumors and a
pronounced infiltration of effector CD8 and CD4 T cells, with no effect on regulatory T cell infiltration compared to
aOX40/aCTLA-4 alone. To be maximally effective, this therapy required expression of both OX40 and CTLA-4 on CD8 T
cells. These data indicate that vaccination targeting cross-presenting dendritic cells with a tumor-associated antigen is a
highly effective immunization strategy that can overcome some of the limitations of current systemic immunotherapeutic
approaches that lack defined tumor-directed antigenic targets.
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Background
Immunotherapy is quickly garnering attention and enthusi-
asm as some patients with metastatic disease have achieved
long-term remission. However, combinations of immuno-
therapies and/or targeted therapies will be needed to
achieve complete tumor regression for a larger portion of
patients. Our lab has been investigating the efficacy of
OX40 agonism in combination with CTLA-4 blockade.
OX40 is costimulatory molecule expressed by both CD4
and CD8 T cells following T cell receptor (TCR) ligation [1].
Preclinical data demonstrate that treatment with agonist
anti-OX40 monoclonal antibodies (aOX40) induced tumor
regression by boosting effector CD8 and CD4 T cell expan-
sion and function [2–6]. Another successful approach is the
blockade of a co-inhibitory molecule, CTLA-4, which limits
an active immune response. Our previous research has
demonstrated that combination aOX40/aCTLA-4 therapy
significantly improved survival in preclinical models [7].
Surprisingly, this therapy also induced a profound Th2 bias
in CD4 T cells. It is known that TCR-mediated recognition
of low-affinity antigens can promote a Th2 bias, which
limits an effective antitumor immune response, and that
promoting a Th1 bias results in more favorable outcomes
for patients [8–13]. In order to circumvent a Th2 bias and
promote a more robust Th1 response, we opted to augment
a CD8 T cell response directly via DEC205 expressing
cross-presenting dendritic cells (DCs) [14]. It was previously
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demonstrated that mice defective in cross-presentation have
impaired tumor rejection and that in cancer, DC function is
frequently impaired [15, 16]. We hypothesized that vaccin-
ation targeting a tumor-associated antigen toward cross-
presenting dendritic cells (aDEC-205/HER2 with poly (I: C))
combined with aOX40/aCTLA-4 immunotherapy would
promote a robust effector CD8 T cell response capable of
clearing established tumors.
Main text
To elaborate on our previous studies, we tested the effect of
combination aOX40/aCTLA-4 therapy on antigen-specific
T cell expansion and the kinetics of this response. Combin-
ation aOX40/aCTLA-4 therapy significantly increased the
frequency, function, and persistence of antigen-specific CD8
T cells in the periphery over time. To determine whether
this was a direct or indirect effect on CD8 T cells, we used
OX40-deficient and human CTLA-4 knock-in transgenic
mice. OX40-/- OT-I cells had a significantly reduced ability
to proliferate, differentiate into effector cells, and produce
inflammatory cytokines following combination therapy, in-
dicating the requirement for OX40. To determine whether
CTLA-4 expression on CD8 T cells was required for the
efficacy of combination therapy, we used transgenic mice in
which the extracellular portion of the mouse CTLA-4
receptor is swapped with the human version (huCTLA-4
mice), rendering them unresponsive to anti-mouse CTLA-4
antagonism [17]. Surprisingly, CTLA-4 expression on CD8
T cells was required to induce maximal expansion and
function of this population following combined aOX40/
aCTLA-4 treatment. Furthermore, CD4 T cells were
required to induce a potent CD8 T cell response. A key ob-
servation we made in our previous study was that aOX40/
aCTLA-4 therapy was not sufficient to improve survival of
mice with larger, more established tumors. Notably, when
aDEC-205/HER2 vaccination was combined with aOX40/
aCTLA-4, we observed regression of established tumors
(100-150 mm2). This corresponded with a significant in-
crease in inflammatory cytokine and chemokine production
by CD4 and CD8 T cells, and a notable decrease in Th2
cytokines from CD4 T cells, which we had observed previ-
ously. The triple combination induced profound CD8 and
CD4 effector Tcell infiltration in the tumor. It is known that
T cell anergy is a major obstacle to effective antitumor
immunity. To investigate whether this triple combination
could overcome T cell anergy, we combined a mouse model
of anergy using POET-1 (probasin ovalbumin expressing
transgenic-1) combined with a spontaneous prostate cancer
model – TRAMP (transgenic adenocarcinoma of the mouse
prostate) transgenic mice [18, 19]. POET-1 mice express
membrane-bound ovalbumin (mOVA) in the prostate
driven by the rat probasin promoter. Thus, POET-1 x
TRAMP (TRAMP-OVA) mice express mOVA as a self/
tumor-associated antigen that renders ovalbumin-specific
CD8 T cells anergic. Combined aOX40/aCTLA-4 therapy
with aDEC-205/OVA vaccination rescued anergic tumor-
specific CD8 T cells and significantly improved their activa-
tion, proliferation, and cytokine production (Fig. 1).
Fig. 1 Vaccination using aDEC-205/HER2 combined with adjuvant poly (I:C) induces dendritic cell maturation and costimulatory molecule expression,
thereby resulting in more efficient antigen presentation to CD8 T cells. Activation of CD8 T cells via the T cell receptor (TCR) and OX40 using an OX40
agonist induces robust CTL activation, while CTLA-4 blockade releases the brakes on the activated CTL. Effector CD8 T cells can now traffic into the
tumor, where they accumulate and induce cancer cell death using cytolytic granule proteins. T cell activation and cancer cell death leads to increased
cytokine (IFN-γ, TNF-α, IL-2) and chemokine (CCL3/MIP-1α; CCL4/MIP-1β; CCL5/RANTES) production leading to additional recruitment of effector T cells.
OX40 agonism and CTLA-4 blockade also lead to CD4 T cell activation and expansion. Together, this robust T cell response results in tumor eradication
and improved long-term survival
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Conclusions
Our recent studies suggest that finding appropriate vac-
cination methods to combine with checkpoint inhibitors
(e.g., aCTLA-4) and costimulatory molecule agonism
(e.g., aOX40) will be more effective at reducing tumor
burden and improving survival than any single agent. In
particular, the use of aOX40/aCTLA-4 alone was insuffi-
cient to eliminate larger, more established tumors, which
may be due to increased Th2-associated cytokines or
tumor-induced anergy [7]. One possible explanation for
the reduced efficacy of combination therapy in the
absence of vaccination is because it relies on TCR-
mediated recognition of endogenous antigens. Due to
mechanisms of central and peripheral tolerance the
majority of these T cells are likely to be of low affinity
for their respective tumor-associated antigens. In the
absence of competition from T cells with higher affinity
or an abundance of antigen, a Th2 response predominates
[20, 21]. By administering both an adjuvant to promote
DC maturation and a tumor-associated antigen targeted
to an endocytic receptor present on DCs, we were able to
very effectively prime an antitumor cytotoxic T lympho-
cyte (CTL) response. CTL activation through the TCR is
known to induce expression of both OX40 and CTLA-4
receptors, thus providing targets for aOX40/aCTLA-4
therapy. This triple combination—using OX40 agonism to
step on the gas, CTLA-4 blockade to release the brakes,
and vaccination using aDEC-205/HER2 to steer the im-
mune response in the right direction—was able to gener-
ate profound CTL infiltration into the tumor leading to
tumor regression (Fig. 1). One possible explanation for the
observed increase in Th1 polarization and concomitant
reduction in Th2 cytokine production following triple
combination therapy is that CTL-mediated cancer cell
death will release an abundance of antigens, including
those derived from over-expressed and/or mutated self-
proteins. CD4 T cell recognition of these epitopes on ma-
ture antigen presenting cells expressing the appropriate
costimulatory molecules would favor a Th1-polarized re-
sponse. These and previous data also suggest an effect on
CD8 T cell differentiation as a possible mechanism for the
increased efficacy of the therapy. Our lab is currently
investigating the molecular mechanisms underlying this
process. Currently, there are multiple clinical trials testing
various combinations of immune-based therapeutic mo-
dalities, including checkpoint inhibitors, targeted therapy
with small molecule inhibitors, adoptive cell therapy,
and standard of care chemotherapy or radiation. Dual
treatment with CTLA-4 and PD-1 blockade (ipilimumab
and nivolumab, respectively) was recently approved, and
while it improves the overall response rate, the majority of
patients succumb to their disease. The incidence of Grade
3-4 toxicities also increases with dual therapy, which is
not surprising given the importance of these two
molecules in preventing rampant autoimmunity. Perhaps
combining a method of vaccination with a checkpoint
inhibitor and a costimulatory molecule agonist, such as
monoclonal antibodies activating OX40, 4-1BB, or GITR,
will provide greater efficacy for patients, as it may more
easily direct the immune response in the direction desir-
ed—away from normal self-antigens and toward a tumor-
associated antigen. In the growing age of bioinformatics
and personalized medicine, it seems that personalized
vaccination is becoming a more feasible possibility for
patients. Combining vaccination using a patient’s own
tumor-associated neoepitopes with checkpoint inhibition
and/or costimulatory molecule agonism will likely pro-
mote a more directed T cell response and may benefit a
majority of patients, even with a minimal baseline pres-
ence of T cells. In fact, it is in this scenario where the
efficacy of OX40 agonists may truly shine.
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